BSE Live
Apr 02, 16:01Prev. Close
5.23
Open Price
5.79
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Key Financial Ratios of DECIPHER LABS (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 0.01 | 0.04 | 0.04 | 2.45 | -0.26 | |
| Diluted EPS (Rs.) | 0.01 | 0.04 | 0.04 | 2.45 | -0.26 | |
| Cash EPS (Rs.) | 0.16 | 0.17 | 0.19 | 2.59 | 0.02 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | -4.68 | -4.70 | -4.74 | -4.78 | -7.85 | |
| Book Value [InclRevalReserve]/Share (Rs.) | -4.68 | -4.70 | -4.74 | -4.78 | -7.85 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 1.21 | 1.19 | 1.19 | 1.13 | 0.53 | |
| PBDIT/Share (Rs.) | 0.17 | 0.18 | -0.04 | 2.76 | 0.02 | |
| PBIT/Share (Rs.) | 0.02 | 0.05 | -0.18 | 2.63 | -0.25 | |
| PBT/Share (Rs.) | 0.01 | 0.05 | -0.19 | 2.48 | -0.26 | |
| Net Profit/Share (Rs.) | 0.01 | 0.04 | 0.04 | 2.45 | -0.26 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 13.64 | 15.40 | -2.95 | 245.18 | 4.00 | |
| PBIT Margin (%) | 1.26 | 4.42 | -15.34 | 233.28 | -47.62 | |
| PBT Margin (%) | 1.08 | 4.00 | -16.27 | 219.91 | -48.17 | |
| Net Profit Margin (%) | 1.08 | 3.20 | 3.77 | 217.57 | -48.17 | |
| Return on Networth / Equity (%) | -0.28 | -0.81 | -0.94 | -51.31 | 0.00 | |
| Return on Capital Employed (%) | 0.17 | 0.81 | -3.31 | -112.46 | -63.07 | |
| Return on Assets (%) | 0.09 | 0.34 | 0.95 | 55.20 | -4.16 | |
| Total Debt/Equity (X) | -0.41 | -0.11 | -0.71 | -0.54 | -1.05 | |
| Asset Turnover Ratio (%) | 8.59 | 10.66 | 25.17 | 25.37 | 8.64 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 0.41 | 0.56 | 0.22 | 0.42 | 0.16 | |
| Quick Ratio (X) | 0.23 | 0.49 | 0.08 | 0.25 | 0.05 | |
| Inventory Turnover Ratio (X) | 1.04 | 2.47 | 1.49 | 1.02 | 0.83 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 100.00 | 100.00 | 100.00 | 100.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 100.00 | 100.00 | 100.00 | 100.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 1.09 | 0.67 | 1.65 | 1.07 | 3.28 | |
| EV/Net Operating Revenue (X) | 2.79 | 1.73 | 4.30 | 2.93 | 19.04 | |
| EV/EBITDA (X) | 20.43 | 11.26 | -145.45 | 1.19 | 475.37 | |
| MarketCap/Net Operating Revenue (X) | 1.56 | 1.59 | 1.60 | 1.69 | 3.56 | |
| Retention Ratios (%) | 100.00 | 100.00 | 100.00 | 100.00 | 0.00 | |
| Price/BV (X) | -0.41 | -0.40 | -0.40 | -0.40 | -0.24 | |
| Price/Net Operating Revenue | 1.57 | 1.60 | 1.60 | 1.69 | 3.56 | |
| Earnings Yield | 0.01 | 0.02 | 0.02 | 1.29 | -0.13 |
26.11.2025
DECIPHER LABS Consolidated September 2025 Net Sales at Rs 4.31 crore, down 26.47% Y-o-Y
24.11.2025
DECIPHER LABS Standalone September 2025 Net Sales at Rs 0.09 crore, up 5.01% Y-o-Y
10.06.2025
DECIPHER LABS Standalone March 2025 Net Sales at Rs 0.23 crore, down 93.27% Y-o-Y
03.06.2025
DECIPHER LABS Consolidated March 2025 Net Sales at Rs 3.50 crore, down 66.95% Y-o-Y
26.11.2025
DECIPHER LABS Consolidated September 2025 Net Sales at Rs 4.31 crore, down 26.47% Y-o-Y
24.11.2025
DECIPHER LABS Standalone September 2025 Net Sales at Rs 0.09 crore, up 5.01% Y-o-Y
10.06.2025
DECIPHER LABS Standalone March 2025 Net Sales at Rs 0.23 crore, down 93.27% Y-o-Y
03.06.2025
DECIPHER LABS Consolidated March 2025 Net Sales at Rs 3.50 crore, down 66.95% Y-o-Y
02.04.2026
02.04.2026
Lupin shares down 2% as arm to acquire 43.38% stake in Multicare Pharma
02.04.2026
02.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth